Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is a neurodegenerative disorder and its etiology is unknown, numerous studies show how different environmental factors can influence the development of disease. miRNAs are involved in several pathologies and their dysregulation contribute to different pathologies, also in neurodegenerative such as Parkinson's disease, Alzheimer's disease, Huntington's disease and Amyotrophic lateral sclerosis. In this study, we profiled the expression of different candidate miRNAs: miR-155, miR-26a, miR-146a, and miR132, in PBMCs of L-dopa treated Parkinson patients and unaffected controls (HCs).We investigated the expression of miRNAs by RT-real time PCR, the results were subjected to statistical analysis. miRNA-155-5p was generally up-regulated in PD patients compared to HCs whereas miRNA-146a-5p was down-regulated in PD patients in comparison to HCs. It is interesting to point out that the expression of miR-155-5p was modified by levodopa treatment, in fact a down-regulation of miR-155-5p in PD patients with the highest dosage was observed. In conclusion, miRNA 155 could not only be a promising target for the anti-inflammatory therapy in PD but also a good candidate as a disease progression biomarker. The role of levodopa in modulating the levels of miRNA 155 requires further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 1×
“Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons, causing symptoms such as muscle rigidity, resting tremor, bradykinesia, and postural instability [1].”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Signaling in innate immunity and inflammation
Newton, K., & Dixit, V. M. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006049 · Cited by 1,513 · cited 1×
“MiRNA 146a acts regulating negatively the powerful pro-inflammatory pathway mediated bynuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), a transcription factor able to regulate inflammation, immunity and cell survival [35] and attenuating the proinflammatory response.”
BackgroundA MicroRNA Feedback Circuit in Midbrain Dopamine Neurons
Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., Hannon, G., & Abeliovich, A. (2007) · Science · doi:10.1126/science.1140481 · Cited by 1,187
Targeting mi R‐155 restores abnormal microglia and attenuates disease in SOD 1 mice
Butovsky, O., Jedrychowski, M. P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D. J., Wu, P. M., Doykan, C. E., Kiner, O., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24304 · Cited by 358 · cited 1×
“In addition, studies on animal models of the two diseases document how the inhibition of this miRNA through the use of complementary oligonucleotides can reduce disease-related dysfunctions [31].”
BackgroundCardoso, A. L., Guedes, J. R., Pereira de Almeida, L., & Pedroso de Lima, M. C. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03514.x · Cited by 336
Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt261 · Cited by 236 · cited 1×
“Numerous studies indicate miR-155 to be over-expressed in inflammatory disorders of the central nervous system such as multiple sclerosis and amyotrophic lateral sclerosis [30].”
BackgroundCopper and Copper Proteins in Parkinson’s Disease
Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., & Rios, C. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/147251 · Cited by 203
Spreading of Alzheimer’s disease inflammatory signaling through soluble micro-RNA
Lukiw, W. J., Alexandrov, P. N., Zhao, Y., Hill, J. M., & Bhattacharjee, S. (2012) · NeuroReport · doi:10.1097/wnr.0b013e32835542b0 · Cited by 90 · cited 1×
“commonly studied in neurodegenerative diseases, but to date only few studies have been conductedin PD patients except formiR-155 that hasonly been studied in a mouse model of Parkinson disease [18-23].”
Background
Cited by
Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 259
MiR-155: An Important Regulator of Neuroinflammation
Zingale, V. D., Gugliandolo, A., & Mazzon, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010090 · Cited by 163
Fan, W., Liang, C., Ou, M., Zou, T., Sun, F., Zhou, H., & Cui, L. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00090 · Cited by 116
“The miR-146a level is decreased in peripheral blood mononuclear cells (PBMCs) and sera of patients with PD (Ma et al., 2016; Caggiu et al., 2018).”
BackgroundEmergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
“…miR-34a-5p, miR-155-5p, miR-24, and miR-195, were found to be significantly elevated, whereas miR-146a, miR-19b, and miR-125b were reported to be reduced in the serum EVs of PD patients compared with healthy controls (Cao et al., 2017; Caggiu et al., 2018; Fan et al., 2020; Grossi et al., 2021).”
BackgroundRastegar-Moghaddam, S. H., Ebrahimzadeh-Bideskan, A., Shahba, S., Malvandi, A. M., & Mohammadipour, A. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01200-z · Cited by 64
Metadata
- Authors
- Caggiu, E., Paulus, K., Mameli, G., Arru, G., Sechi, G. P., & Sechi, L. A.
- Venue
- eNeurologicalSci
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 13
- Pages
- 1-4
- ISSN
- 2405-6502 (ISSN-L)
- OpenAlex
- W2890888588
- Cited by
- 117
- References
- 10
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients. https://app.cochat.ai/papers/10.1016/j.ensci.2018.09.002
- The paper
- Caggiu, E., Paulus, K., Mameli, G., Arru, G., Sechi, G. P., & Sechi, L. A. (2018). Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients. eNeurologicalSci. https://doi.org/10.1016/j.ensci.2018.09.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.